Bristol Myers Squibb (BMY) Change in Receivables (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Change in Receivables for 18 consecutive years, with $1.2 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Receivables rose 144.42% year-over-year to $1.2 billion in Q2 2026; TTM through Jun 2026 was -$678.0 million, a 102.39% decrease from a year earlier, with the FY2025 full-year figure at $295.0 million, up 211.74% from the prior year.
• Change in Receivables was $1.2 billion for Q2 2026 at Bristol Myers Squibb, up from -$1.7 billion in the prior quarter.
• Over five years, Change in Receivables peaked at $1.2 billion in Q2 2026 and troughed at -$1.7 billion in Q1 2026.
• A 5-year average of $65.8 million and a median of $85.5 million in 2022 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables surged 1467.69% in 2024 and tumbled 11146.67% in 2026, its largest moves.
• Over 5 years, Change in Receivables stood at $106.0 million in 2022, then soared by 379.25% to $508.0 million in 2023, then slumped by 128.15% to -$143.0 million in 2024, then jumped by 86.71% to -$19.0 million in 2025, then soared by 6326.32% to $1.2 billion in 2026.
• The last three Change in Receivables figures came in at $1.2 billion (Q2 2026), -$1.7 billion (Q1 2026), and -$19.0 million (Q4 2025), per Business Quant data.